Ameritas Investment Partners Inc. Continues to Hold Position in NxStage Medical, Inc. (NXTM)

Ameritas Investment Partners Inc. continued to hold its position in NxStage Medical, Inc. (NASDAQ:NXTM) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,498 shares of the medical device company’s stock at the close of the 2nd quarter. Ameritas Investment Partners Inc.’s holdings in NxStage Medical were worth $138,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in NXTM. BlackRock Inc. increased its position in NxStage Medical by 38,360.4% during the 1st quarter. BlackRock Inc. now owns 4,413,326 shares of the medical device company’s stock valued at $118,408,000 after purchasing an additional 4,401,851 shares during the period. FMR LLC increased its position in NxStage Medical by 31.8% during the 2nd quarter. FMR LLC now owns 9,860,278 shares of the medical device company’s stock valued at $247,197,000 after purchasing an additional 2,378,077 shares during the period. William Blair Investment Management LLC increased its position in NxStage Medical by 491.6% during the 2nd quarter. William Blair Investment Management LLC now owns 1,959,318 shares of the medical device company’s stock valued at $49,120,000 after purchasing an additional 1,628,114 shares during the period. Redmile Group LLC acquired a new stake in NxStage Medical during the 2nd quarter valued at approximately $16,480,000. Finally, Eagle Asset Management Inc. increased its position in NxStage Medical by 26.6% during the 2nd quarter. Eagle Asset Management Inc. now owns 2,573,603 shares of the medical device company’s stock valued at $64,520,000 after purchasing an additional 540,103 shares during the period. 91.19% of the stock is owned by institutional investors and hedge funds.

NXTM has been the subject of a number of recent analyst reports. Leerink Swann downgraded shares of NxStage Medical from an “outperform” rating to a “market perform” rating and increased their target price for the company from $28.00 to $30.00 in a research report on Tuesday, August 22nd. Zacks Investment Research downgraded shares of NxStage Medical from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. William Blair downgraded shares of NxStage Medical from an “outperform” rating to a “market perform” rating in a research report on Monday, August 7th. Northland Securities reaffirmed a “hold” rating and set a $30.00 price objective on shares of NxStage Medical in a research report on Monday, August 7th. Finally, Canaccord Genuity reaffirmed a “hold” rating and set a $30.00 price objective on shares of NxStage Medical in a research report on Tuesday, October 17th. Two research analysts have rated the stock with a sell rating and eight have assigned a hold rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $30.25.

Shares of NxStage Medical, Inc. (NXTM) opened at $26.65 on Monday. NxStage Medical, Inc. has a 52-week low of $20.45 and a 52-week high of $30.80.

NxStage Medical (NASDAQ:NXTM) last issued its earnings results on Monday, August 7th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03). NxStage Medical had a negative return on equity of 2.43% and a negative net margin of 1.33%. The company had revenue of $92.20 million for the quarter, compared to analysts’ expectations of $96.47 million. During the same period last year, the business earned ($0.03) EPS. NxStage Medical’s quarterly revenue was up .0% compared to the same quarter last year. research analysts predict that NxStage Medical, Inc. will post -0.06 earnings per share for the current year.

In related news, SVP Winifred L. Swan sold 3,500 shares of the stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $29.21, for a total value of $102,235.00. Following the transaction, the senior vice president now directly owns 16,270 shares in the company, valued at approximately $475,246.70. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Matthew W. Towse sold 4,300 shares of the stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $27.27, for a total value of $117,261.00. Following the completion of the transaction, the senior vice president now owns 28,721 shares in the company, valued at $783,221.67. The disclosure for this sale can be found here. Over the last quarter, insiders sold 18,600 shares of company stock worth $526,162. 4.70% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.com-unik.info/2017/11/06/ameritas-investment-partners-inc-continues-to-hold-position-in-nxstage-medical-inc-nxtm.html.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Want to see what other hedge funds are holding NXTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NxStage Medical, Inc. (NASDAQ:NXTM).

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

What are top analysts saying about NxStage Medical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NxStage Medical Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit